




0590
7-2-02

Patent Docket P1869R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Michelle Schaffer et al	Group Art Unit: Unassigned Examiner: Unassigned
Serial No.: 10/066,009 Filed: February 1, 2002 For: CRYSTALLIZATION OF IGF-1	CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on June 19, 2002  Emily Dutra

#9
Plunkett
9/6/02

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

- 37 CFR §1.97(b)**
 - within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
 - within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, or
 - before the mailing of the first Office action on the merits; or
 - before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.
- 37 CFR §1.97(c)**
 - by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.
- 37 CFR §1.97(d)**
 - after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

07/08/2002 14:11:53 00000062 070630 10066009
01 FC:126 180.00 CH

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- 37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- 37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied.

BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1- A-()" (nucleotide) and "BLAST Results B-1 - B-()" (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

- not given
- given for each listed item
- given for only non-English language listed item(s) [Required]
An English language abstract is attached to item 64.
- in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart

Serial No.: 10/066,009
Filed: February 1, 2002

Page 3

application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p).

Respectfully submitted,

GENENTECH, INC.

Date: June 19, 2002

By: Janet E. Hasak
Janet E. Hasak
Reg. No. 28,616
Telephone No. (650) 225-1896



09157

PATENT TRADEMARK OFFICE



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.
P1869R1

Serial No.
10/066,009

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Schaffer, M. et al.

Filing Date
01 Feb 2002

Group
NOT KNOWN

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
	2	4,672,108	09.06.87	Kung et al.		
	3	4,833,233	23.05.89	Carter		
	4	4,876,242	24.10.89	Applebaum, J. et al.		
	5	4,959,351	25.09.90	Grau		
	6	4,988,675	29.01.91	Froesch et al.		
	7	5,028,587	02.07.91	Dorschug et al.		
	8	5,068,224	26.11.91	Fryklund et al.		
	9	5,077,276	31.12.91	Ballard, F. et al.		
	10	5,093,317	03.03.92	Lewis et al.		
	11	5,106,832	21.04.92	Froesch et al.		
	12	5,126,324	30.06.92	Clark et al.		
	13	5,164,370	17.11.92	Ballard, F. et al.		
	14	5,187,151	16.02.93	Clark et al.		
	15	5,202,119	13.04.93	Clark et al.		
	16	5,273,961	28.12.93	Clark		
	17	5,374,620	20.12.94	Clark et al.		
	18	5,461,031	24.10.95	De Felippis		
	19	5,466,670	14.11.95	Dunger, D.B. et al.		
	20	5,470,828	28.11.95	Ballard et al.		
	21	5,504,188	02.04.96	Baker et al.		
	22	5,534,488	09.07.96	Hoffmann		
	23	5,547,930	20.08.96	Balschmidt		
	24	5,569,648	29.10.96	Lewis, M. et al.		
	25	5,597,893	28.01.97	Baker et al.		
	26	5,650,486	22.07.97	De Felippis		
	27	5,714,460	03.02.98	Gluckman et al.		
	28	5,747,642	05.05.98	De Felippis		
	29	5,834,422	10.11.98	Balschmidt		
	30	5,840,680	24.11.98	Balschmidt		
	31	5,898,028	27.04.99	Jensen et al.		
	32	5,898,067	27.04.99	Balschmidt et al.		
	33	5,948,751	07.09.99	Kimer et al.		
	34	5,952,297	14.09.99	De Felippis et al.		
	35	6,127,334	03.10.00	Kimer et al.		

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1869R1	Serial No. 10/066,009
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Schaffer, M. et al.	
		Filing Date 01 Feb 2002	Group NOT KNOWN

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation		
						Yes	No	
	36	668,914	30.08.95	EP				
	37	WO 00/23469	27.04.00	PCT				
	38	WO 91/03253	21.03.91	PCT				
	39	WO 92/11865	23.07.92	PCT				
	40	WO 93/08826	13.05.93	PCT				
	41	WO 93/23067	25.11.93	PCT				
	42	WO 93/23071	25.11.93	PCT				
	43	WO 93/25219	23.12.93	PCT				
	44	WO 94/04569	03.03.94	PCT				
	45	WO 94/16722	04.08.94	PCT				
	46	WO 96/01124	18.01.96	PCT				
	47	WO 96/33216	24.10.96	PCT				
	48	WO 97/00895	09.01.97	PCT				
	49	WO 98/45427	15.10.98	PCT				
	50	WO 99/01476	14.01.99	PCT				
	51	WO 99/38011	29.07.99	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

52	Adams et al., "Structure of Rhombohedral 2 Zinc Insulin Crystals." <u>Nature</u> . 224:491-495 (Nov 1969)
53	Bach and Rechler., "Insulin-Like Growth Factor Binding Proteins." <u>Diabetes Reviews</u> . 3(1):38-61 (1995)
54	Baker et al., "Role of Insulin-Like Growth Factors in Embryonic and Postnatal Growth." <u>Cell</u> . 75:73-82 (Oct 1993)
55	Ballard et al., "Does IGF-I Ever Act Through the Insulin Receptor?" <u>The Insulin-Like Growth Factors and Their Regulatory Proteins</u> , Baxter, eds., Amsterdam: Elsevier pps. 131-138 (1994)
56	Bar et al., "Tissue Localization of Perfused Endothelial Cell IGF Binding Protein is Markedly Altered by Association with IGF-I." <u>Endocrinology</u> . 127(6):3243-3245 (1990)
57	Barinaga, M., "Neurotrophic Factors Enter the Clinic [News]." <u>Science</u> . 264:772-774 (1994)
58	Baserga., "The Insulin-Like Growth Factor 1 Receptor: A Key to Tumor Growth?" <u>Cancer Research</u> 55:249-252 (Jan 1995)
59	Baxter, "Physiological Roles of IGF Binding Proteins" <u>Modern Concepts of Insulin-like Growth Factors</u> , Spencer, eds., Elsevier, New York pps. 371-380 (1991)
60	Baxter., "The Somatomedins: Insulin-Like Growth Factors." <u>Advances in Clinical Chemistry</u> . 25:49-115 (1986)
61	Bayne et al., "Structural Analogs of Human Insulin-Like Growth Factor I with Reduced Affinity for Serum Binding Proteins and the Type 2 Insulin-Like Growth Factor Receptor." <u>J. Bio. Chem.</u> 263:6233-6239 (1988)

Examiner	Date Considered
----------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1869R1

Serial No.

10/066,009

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Schaffer, M. et al.

Filing Date

01 Feb 2002

Group

NOT KNOWN

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

62	Bayne et al., "The C Region of Human Insulin-Like Growth Factor (IGF) I is Required for High Affinity Binding to the Type 1 IGF Receptor." <u>J. Bio. Chem.</u> 264(19):11004-11008 (1988)
63	Bayne et al., "The Roles of Tyrosines 24, 31, and 60 in the High Affinity Binding of Insulin-Like Growth Factor-I to the Type I Insulin-Like Growth Factor Receptor." <u>J. Bio. Chem.</u> 265(26):15648-15652 (Sep 15, 1990)
64	Binoux, M., "Recent Data on Somatomedins (Insulin-Like Growth Factors)." <u>Annales d'Endocrinologie</u> (English Abstract Included) 41:157-192 (1980)
65	Blundell et al., "Insulin-Like Growth Factor: A Model for Tertiary Structure Accounting for Immunoreactivity and Receptor Binding." <u>Proc. Natl. Acad. Sci. USA</u> 75(1):180-184 (Jan 1978)
66	Blundell et al., "Tertiary Structures, Receptor Binding, and Antigenicity of Insulinlike Growth Factors." <u>Federation Proc.</u> 42:2592-2597 (1983)
67	Bondy, C., "Clinical Uses of Insulin-Like Growth Factor I." <u>Annals of Internal Medicine.</u> 120:593-601 (1994)
68	Buckbinder et al., "Induction of the Growth Inhibitor IGF-Binding Protein 3 by p53." <u>Nature.</u> 377:646-649 (Oct 1995)
69	Cascieri et al., "Mutants of Human Insulin-Like Growth Factor I with Reduced Affinity for the Type 1 Insulin-Like Growth Factor Receptor." <u>Biochemistry</u> 27(9):3229-3233 (May 3, 1988)
70	Cascieri et al., "Structural Analogs of Human Insulin-Like Growth Factor (IGF) I with Altered Affinity for Type 2 IGF Receptors." <u>J. Bio. Chem.</u> 264:2199-2202 (1989)
* 71	Cavanagh et al. <u>Protein NMR Spectroscopy: Principles and Practice.</u> , New York:Academic Press, Inc. (1996)
72	Clemmons and Van Wyk., "Somatomedin: Physiological Control and Effects on Cell Proliferation." <u>Handbook Exp. Pharmacol.</u> 57:161-208 (1981)
73	Clemmons et al., "Competition for Binding to Insulin-Like Growth Factor (IGF) Binding Protein-2, 3, 4, and 5 by the IGFs and IGF Analogs." <u>Endocrinology.</u> 131(2):890-895 (Aug 1992)
74	Clemmons et al., "Discrete Alterations of the Insulin-Like Growth Factor I Molecule Which Alter Its Affinity for Insulin-Like Growth Factor-Binding Proteins Result in Changes in Bioactivity." <u>J. Bio. Chem.</u> 265(21):12210-12216 (1990)
75	Clemmons et al., "The Role of Insulin-Like Growth Factors in the Nervous System." <u>Anal. NY Acad. Sci. USA</u> 692:10-21 (1993)
76	Clore et al., "Stereospecific Assignment of β -Methylene Protons in Larger Proteins Using 3D ^{15}N -Separated Hartmann-Hahn and ^{13}C -Separated Rotating Frame Overhauser Spectroscopy." <u>J. Biomol. NMR</u> 1:13-22 (1991)
77	Cohen et al., "Biological Effects of Prostate Specific Antigen as an Insulin-Like Growth Factor Binding Protein-3 Protease." <u>J. Endocrinology.</u> 142:407-415 (1994)
78	Cohen et al., "Insulin-Like Growth Factors (IGFs), IGF Receptors, and IGF-Binding Proteins in Primary Cultures of Prostate Epithelial Cells." <u>J. Clin. Endocrin. & Metab.</u> 73:401-407 (1991)
79	Cohen et al., "The IGF Axis in the Prostate." <u>Horm. & Metab. Res.</u> 26:81-84 (1994)
80	Cooke et al., "Solution Structure of Human Insulin-Like Growth Factor 1: A Nuclear Magnetic Resonance and Restrained Molecular Dynamics Study" <u>Biochemistry</u> 30:5484-5491 (1991)
81	Cornilescu et al., "Protein Backbone Angle Restraints From Searching a Database for Chemical Shift and Sequence Homology." <u>J. Biomol. NMR</u> 13:289-302 (1999)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




FORM PTO-1449	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1869R1	Serial No. 10/066,009
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Schaffer, M. et al.	
		Filing Date 01 Feb 2002	Group NOT KNOWN

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)


82	Culig et al., "Androgen Receptor Activation in Prostatic Tumor Cell Lines by Insulin-Like Growth Factor-I, Keratinocyte Growth Factor, and Epidermal Growth Factor." <u>Cancer Research</u> . 54:5474-5478 (1994)
83	Cullen et al., "Insulin-Like Growth Factor Receptor Expression and Function in Human Breast Cancer." <u>Cancer Research</u> . 50:48-53 (1990)
84	Daughaday and Rotwein., "Insulin-Like Growth Factors I and II. Peptide, Messenger Ribonucleic Acid and Gene Structures, Serum, and Tissue Concentrations." <u>Endocrin. Rev.</u> 10(1):68-91 (1989)
85	De Meyts., "The Structural Basis of Insulin and Insulin-Like Growth Factor-I Receptor Binding and Negative Co-Operativity, and its Relevance to Mitogenic Versus Metabolic Signalling." <u>Diabetologia</u> . (Suppl. 2) 37:S135-S148 (1994)
86	De Wolf et al., "Solution Structure of a Mini IGF-1." <u>Protein Sci.</u> 5:2193-2202 (1996)
87	Derewenda et al., "Phenol Stabilizes More Helix in a New Symmetrical Zinc Insulin Hexamer." <u>Nature</u> . 338:594-596 (Apr 1989)
88	Dubaquie and Lowman, "Total Alanine-Scanning Mutagenesis of Insulin-Like Growth Factor I (IGF-I) Identifies Differential Binding Epitopes for IGFBP-1 and IGFBP-3" <u>Biochemistry</u> 38(20):6386-6396 (1999)
89	Dubaquie et al., "Binding Protein-3-Selective Insulin-Like Growth Factor I Variants: Engineering, Biodistributions, and Clearance." <u>Endocrinology</u> . 142(1):165-173 (Jan 2001)
90	Duerr et al., "Insulin-Like Growth Factor-1 Enhances Ventricular Hypertrophy and Function During the Onset of Experimental Cardiac Failure." <u>J. Clin. Invest.</u> 95:619-627 (1995)
91	Einstein and Low., "Insulin: Some Shrinkage Stages of Sulfate and Citrate Crystals." <u>Acta Crystallogr.</u> 15:32-34 (1962)
92	Elahi et al., "Hemodynamic and Metabolic Responses to Human Insulin-Like Growth Factor I (IGF-I) in Men." <u>Modern Concepts of Insulin-Like Growth Factors</u> , Spencer, EM, ed., New York:Elsevier Science Publ. Co. pps. 219-224 (1991)
93	Fejzo et al., "The SHAPES Strategy: An NMR-Based Approach for Lead Generation in Drug Discovery." <u>Chemistry & Biology</u> . 6:755-769 (1999)
94	Feyen et al., "Recombinant Human [Cys ²⁸¹]Insulin-Like Growth Factor-Binding Protein 2 Inhibits Both Basal and Insulin-Like Growth Factor I-Stimulated Proliferation and Collagen Synthesis in Fetal Rat Calvariae." <u>J Bio. Chem.</u> 266:19469-19474 (1991)
95	Figueroa et al., "Recombinant Insulin-Like Growth Factor Binding Protein-1 Inhibits IGF-I, Serum, and Estrogen-Dependent Growth of MCF-7 Human Breast Cancer Cells." <u>J. Cell Phys.</u> 157:229-236 (1993)
96	Froesch et al., "Metabolic and Therapeutic Effects of Insulin-Like Growth Factor I" <u>Horm. Res.</u> 42:66-71 (1994)
97	Garrett et al., "Crystal Structure of the First Three Domains of the Type-1 Insulin-Like Growth Factor Receptor." <u>Nature</u> . 394(6691):395-399 (Jul 23, 1998)
98	Guler et al., "Recombinant Human Insulin-Like Growth Factor 1 Stimulates Growth and has Distinct Effects on Organ Size in Hypophysectomized Rats." <u>Proc. Natl. Acad. Sci. USA</u> 85:4889-4893 (1988)
99	Hammerman and Miller., "The Growth Hormone Insulin-Like Factor Axis in Kidney Revisited." <u>Am. J. Physiol.</u> 265:F1-F14 (1993)
100	Hammerman and Miller., "Therapeutic Use of Growth Factors in Renal Failure." <u>J. Am. Soc. Nephrol.</u> 5:1-11 (1994)
101	Hasegawa et al., "The Free Form of Insulin-Like Growth Factor I Increases in Circulation During Normal Human Pregnancy." <u>J. Clin. Endocrinol. Metabol.</u> 80:3284-3286 (1995)

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1869R1	Serial No. 10/066,009
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Schaffer, M. et al.	
				Filing Date 01 Feb 2002	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
102	Hizuka et al., "Measurement of Free Form of Insulin-Like Growth Factor I in Human Plasma." <u>Growth Regulation</u> . 1:51-55 (1991)				
103	Horney et al., "Elevated Glucose Increases Mesangial Cell Sensitivity to Insulin-Like Growth Factor I." <u>Am. J. Physiol.</u> 274:F1045-F1053 (1998)				
104	Hsing et al., "Regulation of Apoptosis Induced by Transforming Growth Factor- β 1 in Nontumorigenic and Tumorigenic Rat Prostatic Epithelial Cell Lines." <u>Cancer Research</u> . 56:5146-5149 (1996)				
105	Humbel., "Insulin-Like Growth Factors I and II." <u>European Journal of Biochemistry</u> . 190:445-462 (1990)				
106	Huynh et al., "Estradiol and Antiestrogens Regulate a Growth Inhibitory Insulin-Like Growth Factor Binding Protein 3 Autocrine Loop in Human Breast Cancer Cells." <u>J. Bio. Chem.</u> 271(2):1016-1021 (1996)				
107	Isaksson et al., "Growth Hormone Stimulates Longitudinal Bone Growth Directly." <u>Science</u> . 216:1237-1239 (1982)				
108	Isaksson et al., "Mechanism of the Stimulatory Effect of Growth Hormone on Longitudinal Bone Growth." <u>Endocrine Reviews</u> . 8(4):426-438 (1987)				
109	Iwamura et al., "Insulin-Like Growth Factor I: Action and Receptor Characterization in Human Prostate Cancer Cell Lines." <u>Prostate</u> . 22:243-252 (1993)				
110	Jabri et al., "Adverse Effects of Recombinant Human Insulin-Like Growth Factor I in Obese Insulin-Resistant Type II Diabetic Patients." <u>Diabetes</u> 43:369-374 (1994)				
111	Janin and Chothia., "The Structure of Protein-Protein Recognition Sites." <u>J. Bio. Chem.</u> 265(27):16027-16030 (1990)				
112	Jansson et al., "The Insulin-Like Growth Factor (IGF) Binding Protein 1 Binding Epitope on IGF-I Probed by Heteronuclear NMR Spectroscopy and Mutational Analysis." <u>J. Bio. Chem.</u> 273(38):24701-24707 (September 18, 1998)				
113	Jones and Clemmons., "Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions." <u>Endocrine Rev.</u> 16(1):3-34 (1995)				
114	Juul et al., "Serum Concentrations of Free and Total Insulin-Like Growth Factor-I, IGF Binding Proteins -1 and -3 and IGFBP-3 Protease Activity in Boys with Normal or Precocious Puberty." <u>Clin. Endocrin.</u> 44:515-523 (1996)				
115	Juul et al., "Serum Insulin-Like Growth Factor-I in 1030 Healthy Children, Adolescents, and Adults: Relation to Age, Sex, Stage of Puberty, Testicular Size, and Body Mass Index." <u>J. Clin. Endocrin. & Metab.</u> 78(8):744-752 (1994)				
116	Juul et al., "Serum Levels of Insulin-Like Growth Factor (IGF)-Binding Protein-3 (IGFBP-3) in Healthy Infants, Children, and Adolescents: The Relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, Age, Sex, Body Mass Index, and Pubertal Maturation." <u>J. Clin. Endocrin. & Metab.</u> 80:2534-2542 (1995)				
117	Kerr et al., "Effect of Insulin-like Growth Factor-1 on the Responses to and Recognition of Hypoglycemia in Humans: A Comparison with Insulin." <u>J. Clin. Invest.</u> 91:141-147 (1993)				
118	Kuzuya et al., "Trial of Insulinlike Growth Factor I Therapy for Patients with Extreme Insulin Resistance Syndromes." <u>Diabetes</u> . 42:696-705 (1993)				
119	Laajoki et al., "Secondary Structure Determination of ^{15}N -Labelled Human Long-[Arg-3]-Insulin-Like Growth Factor 1 by Multidimensional NMR Spectroscopy." <u>FEBS Letters</u> 420:97-102 (1997)				
120	Laajoki et al., "Solution Structure and Backbone Dynamics of Long-[Arg ³]Insulin-Like Growth Factor-I." <u>J. Bio. Chem.</u> 275(14):10009-10015 (2000)				
121	Lee et al., "A Pulsed Field Gradient Isotope-Filtered 3D ^{13}C HMQC-NOESY Experiment for Extracting Intermolecular NOE Contacts in Molecular Complexes." <u>FEBS Letters</u> 350:87-90 (1994)				
Examiner				Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.
P1869R1

Serial No.
10/066,009

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Schaffer, M. et al.

Filing Date
01 Feb 2002

Group
NOT KNOWN


OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

122	Lee et al., "Activation of Estrogen Receptor-Mediated Gene Transcription by IGF-I in Human Breast Cancer Cells." <u>J. Endocrinol.</u> 152:39-47 (1997)
123	Lee et al., "Regulation and Function of Insulin-Like Growth Factor-Binding Protein-1." <u>Proc. Soc. Exp. Biol. & Med.</u> 204:4-29 (1993)
124	LeRoith et al., "Insulin-Like Growth Factors and Cancer." <u>Annals of Internal Medicine.</u> 122(1):54-59 (Jan 1995)
125	LeRoith., "Editorial: Insulin-Like Growth Factor I Receptor Signaling-- Overlapping or Redundant Pathways?" <u>Endocrinology.</u> 141(4):1287-1288 (2000)
126	Lewitt and Baxter, "Insulin-Like Growth Factor-Binding Protein-1: A Role in Glucose Counterregulation?" <u>Mol. Cell. Endocrin.</u> 79(1-3):C147-C152 (1991)
127	Lewitt et al., "Insulin-like Growth Factor-binding Protein-1 Modulates Blood Glucose Levels" <u>Endocrinology</u> 129(4):2254-2256 (1991)
128	Lieberman et al., "Effects of Recombinant Human Insulin-Like Growth Factor-I (rhIGF-I) on Total and Free IGF-I Concentrations, IGF-Binding Proteins, and Glycemic Response in Humans." <u>J. Clin. Endocrinol. & Metab.</u> 75(1):30-36 (1992)
129	Liu et al., "Insulin-Like Growth Factor-I Affects Perinatal Lethality and Postnatal Development in a Gene Dosage-Dependent Manner: Manipulation Using the Cre/loxP System in Transgenic Mice." <u>Molecular Endocrinology</u> 12(9):1452-1462 (1998)
130	Liu et al., "Mice Carrying Null Mutations of the Genes Encoding Insulin-Like Growth Factor I (Igf-1) and Type I IGF Receptor (Igf1r)." <u>Cell.</u> 75:59-72 (Oct 1993)
131	Long et al., "Loss of the Metastatic Phenotype in Murine Carcinoma Cells Expressing an Antisense RNA to the Insulin-Like Growth Factor Receptor." <u>Cancer Research.</u> 55:1006-1009 (1995)
132	Lowman et al., "Molecular Mimics of Insulin-Like Growth Factor 1 (IGF-1) for Inhibiting IGF-1: IGF-Binding Protein Interactions." <u>Biochemistry</u> 37(25):8870-8878 (1998)
133	McGuire et al., "Regulation of Insulin-Like Growth Factor-Binding Protein (IGFBP) Expression by Breast Cancer Cells: Use of IGFBP-1 as an Inhibitor of Insulin-Like Growth Factor Action." <u>J. Natl. Cancer Institute</u> 84(17):1336-1341 (1992)
*134	McPherson, Alexander. <u>Preparation and Analysis of Protein Crystals.</u> (Second Edition), Malabar, FL:Robert E. Krieger Publishing Comp. (1989)
135	Morrow et al., "Recombinant Human (rh) IGF-1 Reverses Hyperglycemia and Improves Insulin Sensitivity in Severe Insulin Resistance" <u>Diabetes-53rd Annual Meeting, June 12-15, 1993</u> (Suppl. 1, abstract No. 269) 42:83A (1993)
136	Oh et al., "Antiproliferative Actions of Insulin-Like Growth Factor Binding Protein (IGFBP)-3 in Human Breast Cancer Cells." <u>Prog. Growth Factor Res.</u> 6(2-4):503-512 (1995)
137	Oh et al., "Characterization of the Affinities of Insulin-Like Growth Factor (IGF)-Binding Proteins 1-4 for IGF-I, IGF-II, IGF-I/Insulin Hybrid, and IGF-I Analogs." <u>Endocrinology.</u> 132:1337-1344 (1993)
138	Oh et al., "Insulin-Like Growth Factor (IGF)-Independent Action of IGF-Binding Protein-3 in Hs578T Human Breast Cancer Cells." <u>J. Bio. Chem.</u> 268(20):14964-14971 (1993)
139	Peterkofsky et al., "Elevated Activity of Low Molecular Weight Insulin-Like Growth Factor-Binding Proteins in Sera of Vitamin C-Deficient and Fasted Guinea Pigs" <u>Endocrinology</u> 128(4):1769-1779 (1991)
140	Pietrzkowski et al., "Inhibition of Cellular Proliferation by Peptide Analogues of Insulin-Like Growth Factor 1." <u>Cancer Research.</u> 52:6447-6451 (1992)
141	Powell-Braxton et al., "IGF-I is Required for Normal Embryonic Growth in Mice." <u>Genes Dev.</u> 7:2609-2617 (1993)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No. P1869R1	Serial No. 10/066,009
----------------------------	--------------------------

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Schaffer, M. et al.

Filing Date 01 Feb 2002	Group NOT KNOWN
----------------------------	--------------------

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

142	Pratt and Pollak., "Insulin-Like Growth Factor Binding Protein 3 (IGF-BP3) Inhibits Estrogen-Stimulated Breast Cancer Cell Proliferation." <u>Biophys. Res. Comm.</u> 198(1):292-297 (1994)
143	Quin et al., "Acute Response to Recombinant Insulin-Like Growth Factor I in a Patient with Mendenhall's Syndrome." <u>New Engl. J. Med.</u> 323(20):1425-1426 (1990)
144	Quinn et al., "Insulin-Like Growth Factor Expression in Human Cancer Cell Lines." <u>J. Bio. Chem.</u> 271(19):11477-11483 (1996)
145	Rajah et al., "Insulin-Like Growth Factor (IGF)-Binding Protein-3 Induces Apoptosis and Mediates the Effects of Transforming Growth Factor-β1 on Programmed Cell Death through a p53- and IGF-Independent Mechanism." <u>J. Bio. Chem.</u> 272(18):12181-12188 (1997)
146	Reilly and Fairbrother., "A Novel Isotope Labeling Protocol for Bacterially Expressed Proteins." <u>J. Biomol. NMR</u> 4:459-462 (1994)
147	Rinderknecht and Humbel, "Amino-Terminal Sequences of Two Polypeptides From Human Serum with Nonsuppressible Insulin-Like and Cell-Growth-Promoting Activities: Evidence for Structural Homology with Insulin B Chain." <u>Proc. Natl. Acad. Sci. USA</u> 73(12):4379-4381 (1976)
148	Rinderknecht and Humbel., "The Amino Acid Sequence of Human Insulin-Like Growth Factor I and Its Structural Homology with Proinsulin." <u>Journal of Biological Chemistry</u> 253(8):2769-2776 (1978)
149	Rohlik et al., "An Antibody to the Receptor for Insulin-Like Growth Factor I Inhibits the Growth of MCF-7 Cells in Tissue Culture." <u>Biochem. & Biophys. Res. Comm.</u> 149(1):276-281 (Nov 1987)
150	Saad et al., "Low-Doses of Insulin-Like Growth Factor-I Improve Insulin Sensitivity." <u>Diabetologia</u> . (Abstract 152) 37:A40 (Supp. 1 1994)
151	Sato et al., "Three-Dimensional Structure of Human Insulin-Like Growth Factor-I (IGF-I) Determined by ¹ H-NMR and Distance Geometry." <u>Int. J. Pep. Protein Res.</u> 41:433-440 (1993)
152	Schalch et al., "Short-Term Effects of Recombinant Human Insulin-Like Growth Factor I on Metabolic Control of Patients with Type II Diabetes Mellitus" <u>J. of Clinical Endocrinology & Metabolism</u> 77(6):1563-1568 (1993)
153	Schalch et al., "Short-Term Metabolic Effects of Recombinant Human Insulin-Like Growth Factor I (rhIGF-I) in Type II Diabetes Mellitus." <u>Modern Concepts of Insulin-Like Growth Factors.</u> , Spencer, ed., New York:Elsevier Science Publ. Co. pps. 705-713 (1991)
154	Schlechter et al., "Evidence Suggesting that the Direct Growth-Promoting Effect of Growth Hormone on Cartilage In Vivo is Mediated by Local Production of Somatomedin." <u>Proc. Natl. Acad. Sci. USA</u> 83:7932-7934 (1986)
155	Schoenle et al., "Recombinant Human Insulin-Like Growth Factor I (rhIGF I) Reduces Hyperglycaemia in Patients with Extreme Insulin Resistance." <u>Diabetologia</u> . 34:675-679 (1991)
156	Sjogren et al., "Liver-Derived Insulin-Like Growth Factor I (IGF-I) is the Principal Source of IGF-I in Blood but is Not Required for Postnatal Body Growth in Mice." <u>Proc. Natl. Acad. Sci. USA</u> 96:7088-7092 (1999)
157	Smith et al., "Essential Role of Growth Hormone in Ischemia-Induced Retinal Neovascularization." <u>Science</u> . 276:1706-1709 (1997)
158	Steller et al., "Overexpression of the Insulin-Like Growth Factor-1 Receptor and Autocrine Stimulation in Human Cervical Cancer Cells." <u>Cancer Research</u> . 56:1761-1765 (1996)
159	Stracke et al., "The Type I Insulin-Like Growth Factor Receptor is a Motility Receptor in Human Melanoma Cells." <u>J. Bio. Chem.</u> 264(36):21544-21549 (Dec 1989)
160	Suikkari et al., "Insulin Regulates the Serum Levels of Low Molecular Weight Insulin-Like Growth Factor-Binding Protein." <u>J. Clin. Endocrin. Metabol.</u> 66:266-272 (1988)
161	Tollefsen and Thompson., "The Structural Basis for Insulin-Like Growth Factor I Receptor High Affinity Binding." <u>J. Bio. Chem.</u> 263(31):16267-16273 (1988)

Examiner	Date Considered
----------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

